An ambitious biotech with a different perspective on drug discovery.

 

 

ABOUT PROSETTA

Prosetta Biosciences, Inc. is a 12-year old biotechnology company focused on developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS).

Our CFPSS drug discovery platform allows for identification of small molecule drugs which may be missed with traditional pharma screening methods.

Prosetta has successfully produced highly potent compounds which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids and display activity against multiple strains of many viral families.

News

Prosetta announces closing of private placement with Alger Management and Takeda Pharmaceutical Company, limited, among others.